Showing results (281-290 of 777) with videos related to

Sort By:
Pageof 78
Blood|August 5, 2004
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cellsPierfrancesco Tassone, Victor S Goldmacher, Paola Neri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myelomaLanie K Francis, Yazan Alsayed, Xavier Leleu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Moving toward individualized cancer therapiesGiovanni Tonon, Kenneth C Anderson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2011
Disentangling the myeloma webGiovanni Tonon, Kenneth C Anderson
CA: a Cancer Journal for Clinicians|October 1, 2014
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and backGiada Bianchi, Kenneth C Anderson
Haematologica|October 15, 2020
Multiple myeloma: the (r)evolution of current therapy and a glance into futureAnnamaria Gulla, Kenneth C Anderson
Expert Opinion on Drug Safety|February 27, 2020
The safety of current and emerging therapies for multiple myelomaOmar Nadeem, Kenneth C Anderson
Oncology (Williston Park, N.Y.)|June 7, 2005
Treatment options for older myeloma patients. From the Multiple Myeloma Research FoundationKenneth C Anderson, Antonio Palumbo,
Pageof 78